Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Public ClinicalTrials.gov record NCT00887575. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Trial of Neoadjuvant Sunitinib Administered With Weekly Paclitaxel/Carboplatin in Patients With Locally Advanced Triple-Negative Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial will examine the combination of sunitinib plus paclitaxel and carboplatin as neoadjuvant treatment for locally advanced breast cancer.
Study identification
- NCT ID
- NCT00887575
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 54 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2009
- Primary completion
- Jun 30, 2013
- Completion
- Aug 31, 2014
- Last update posted
- Sep 6, 2016
2009 – 2014
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Holy Cross Hospital | Fort Lauderdale | Florida | 33308 | — |
| Florida Cancer Specialists North | Fort Myers | Florida | 33916 | — |
| Florida Cancer Specialists South | Fort Myers | Florida | 33916 | — |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | — |
| Providence Medical Group | Terre Haute | Indiana | 47802 | — |
| Baptist Hospital East | Louisville | Kentucky | 40207 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| National Capital Clinical Research Consortium | Bethesda | Maryland | 20817 | — |
| St. Louis Cancer Care | Chesterfield | Missouri | 63017 | — |
| Nebraska Methodist Cancer Center | Omaha | Nebraska | 68114 | — |
| Hematology Oncology Associates of Northern NJ | Morristown | New Jersey | 07960 | — |
| Cancer Centers of Southwest Oklahoma | Lawton | Oklahoma | 73505 | — |
| Family Cancer Center | Collierville | Tennessee | 38017 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37023 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00887575, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 6, 2016 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00887575 live on ClinicalTrials.gov.